Mitotane Market
Mitotane market report offers accurate region-wise market projections and forecasts, market share, size, segment-wise analysis, regulatory framework assessment, opportunities and challenges for stakeholders, and impact of key industry trends.
Global Market Study on Mitotane: Rising Demand for Adjuvant Therapy Offers Impetus
- Report code : PMRREP30052 |
- Industry : Life Sciences & Transformational Health |
- Published On : Aug-2019 |
- Pages : 206 Pages |
- Format :
Mitotane Market to Witness Healthy Growth with Expanding Patient Pool
Each year, an estimated ~10-15 per million people globally are affected by Cushing’s syndrome. Pituitary adenomas, a prominent disease indication in Cushing’s syndrome, accounts for ~70% of cases in adults and ~65% of cases in children. Cushing’s syndrome is most common in adults with the age group of 20-50 and more prevalent among females. However, the occurrence of adrenocortical carcinoma is rare malignancy with an incidence of ~0.7-2.0 cases/million habitants/year. The disease can occur at any age. Women are most frequently affected by the disease and therefore, have significant share in patient pool. Adrenal tumors are found in about 1 in every 10 people and is growing significantly every year.
With the increasing incidence of both the diseases each year, the treatment for the same using mitotane is likely to increase in the upcoming years. The mitotane market is expected to grow with a CAGR of ~ 5% in the forecast period.
Late Recurrences at Early Stage of Cushing’s Syndrome Driving the Adoption of Mitotane
Cushing’s syndrome is one of the common ailment affecting adults in the age group of 30 to 50. It is likely that patients who have taken glucocorticoids can also develop Cushing’s syndrome. Late detection and diagnosis is one of the major factor behind the market’s growth, owing to the high purchasing power of adults and growing healthcare insurance. It is estimated that ~10 million Americans take glucocorticoids each year, and this is anticipated to boost the market. Adrenocortical carcinoma could be as high as ~8.7% in autopsy studies and ~4% in in radiology-based studies, exhibiting an average prevalence rate of ~3% in those over the age of 50 years globally. It has been reported that ~75-85% of adrenocortical carcinoma patients will have a relapse after radical resection. Thus, with a high recurrence rate, use of adjuvant therapy with mitotane has increased globally.
Increasing Demand for Adjuvant Therapy Anticipated to Drive the Market
With a high recurrence rate and poor outcome of adrenocortical carcinoma, use of adjuvant therapy followed by surgical resection of tumor is rising. Due to the mitotane’s anti-carcinogenic activity, it has been used extensively in such settings with few conflicting results. In one of the study, it was found that adrenocortical carcinoma patients treated with streptozotocin had a significantly high disease-free survival rate than non-treated patients. It has also been reported that adjuvants with mitotane can improve the recurrence-free survival rate. Despite all pros and cons, mitotane still remains one of the most commonly used therapeutic agent in the treatment of adrenocortical carcinoma, especially for the adjuvant use.
Significant Commercial Sales Partnerships with Market Leaders Driving the Mitotane Market
Over the years, the mitotane market is growing due to the successful commercialization of drugs, its sales, and marketing agreements. For instance, in Jan 2019, Medunik Canada signed an exclusive agreement with HRA pharma for commercialization of Lysodren® (Mitotane) in Canada. In an event in March 2018, moksha8 Brasil announced a strategic agreement and partnership with HRA Pharma, to commercialize the sales of Lysodren in the South America market. This development was observed as the first step to build an oncology treatment line in the mitotane market. However, major manufacturing breakthrough came in Sept 2017, when one of the fatsest-growing healthcare company, HRA Pharma, acquired Lysodren® (Mitotane tablets) from Bristol-Myers Squibb Company.
Mitotane Market: Competitive Landscape
This section of the mitotane market report feature profiles of the key players operating in the mitotane market based on their marketing and differential strategies. Examples of some of the key players featured in this report includes Bristol-Myers Squibb Company and HRA Pharma.
Key manufacturers operating in the mitotane market are keen on implementing new and differentiating strategies to meet not only the product demand, but also to lead the regional market. These companies are focused on leveraging their global reach, creating new sales opportunities, leveraging their existing client base for growth prospects & development, joint ventures, partnerships, and mergers & acquisitions.
Mitotane Market: Additional Questions Answered
Some of the additional questions addressed in this report on the mitotane market are as follows:
- What is the revenue potential of the mitotane markets across Latin America, East & South Asia, and MEA?
- Who are the key competitors and what are their portfolios in the mitotane market?
- What are the major challenges influencing the growth of the mitotane market?
- How is intervention from regulatory authorities shaping the growth of the mitotane market?
Research Methodology
The mitotane market has been assessed based on an epidemiology-based approach. The market was studied by estimating the base year market side in different regions/countries. In addition, the market was estimated based on the usage of reagent kits in the top 20 countries worldwide. Other qualitative factors analyzed during market value estimation includes awareness about the usage of mitotane, which include prescription pattern, drug adoption rate, and the availability of mitotane tablets. This information was further validated with rigorous primary research such as interviews, surveys, in-person interactions, and viewpoints of seasoned analysts, as well as secondary research, which includes verified paid sources, authentic trade journals, and resourceful databases. The research study on the mitotane market also includes top trends and macro as well as microeconomic factors shaping the mitotane market. With this approach, the report on the mitotane market estimates the industry attractiveness of every major segment in the mitotane market during the forecast period.
A recent market study published by PMR about the mitotane market during 2014-2028 and forecast for 2019-2029 consists of a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as current growth parameters of the mitotane market, the growth prospects of the market are obtained with maximum precision.
The report features key factors that are likely to significantly impact the development of the mitotane market during the forecast period. This can help market players modify their manufacturing and marketing strategies to envisage maximum growth of the mitotane market in the upcoming years. The report provides detailed information about the current and future growth prospects of the mitotane market in the most comprehensive manner for better understanding of readers.
Chapter 01 – Executive Summary
The report commences with the executive summary of the mitotane market, which includes a summary of the key findings and statistics of the market. It also includes the market value (US$ million) estimates of prominent segments of the mitotane market.
Chapter 02 – Market Overview
In this chapter, readers can find the definition and detailed taxonomy of the mitotane market, which will help them understand the basic information about the mitotane market. This chapter also highlights the inclusions and exclusions, which help readers understand the scope of the mitotane market report.
Chapter 03 – Key Market Trends
This chapter of the report provides the key market trends that are expected to impact the market growth significantly during the forecast period. Detailed industry trends are provided in this section, along with the key market developments and product innovations.
Chapter 04 – Key Success Factors
This chapter includes key success factors of the market. It includes product adoption & usage analysis, reimbursement scenarios, disease epidemiology, and key regulations and off label use of mitotane.
Chapter 05 – Global Mitotane Market Demand Analysis 2014-2018 and Forecast 2019-2029
This chapter includes detailed analysis of the historical mitotane market, along with an opportunity analysis of the future. Readers can also find the absolute opportunity for the current year (2019 – 2020), and an incremental opportunity for the forecast period.
Chapter 06 – Market Background
This chapter explains the key macro-economic factors that are expected to influence the growth of the mitotane market over the forecast period. Along with the macroeconomic factors, this section also highlights the opportunity analysis for the mitotane market. This chapter also highlights the key market dynamics of the mitotane market, which includes drivers, restraints, trends, and opportunities. Moreover, readers will understand key trends followed by prominent manufacturers in the mitotane market.
Chapter 07 – Global Mitotane Market Analysis 2014 - 2018 & Forecast 2019 – 2029, by Indication
Based on the indication, the mitotane market is segmented into Adrenal Cortical Carcinoma and Cushing's syndrome. In this chapter, readers can find information about the key trends and developments in the mitotane market and market attractiveness analysis based on the indication.
Chapter 08 – Global Mitotane Market Analysis 2014 - 2018 & Forecast 2019 - 2029, by Distribution Channel
This chapter provides details about the mitotane market based on the distribution channel, and has been classified into hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. In this chapter, readers can understand the market attractiveness analysis based on the distribution channel.
Chapter 09 – Global Mitotane Market Analysis 2014 - 2018 & Forecast 2019 - 2029, by Region
This chapter explains how the mitotane market will grow across various geographic regions such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA).
Chapter 10 – North America Mitotane Market Analysis 2014 - 2028 & Forecast, 2019 - 2029
This chapter includes detailed analysis of the growth of the North America mitotane market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find regional trends, regulations, and market growth based on end users and countries in North America.
Chapter 11 – Latin America Mitotane Market Analysis 2014 - 2028 & Forecast 2019 - 2029
Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting the growth of the Latin America mitotane market. This chapter also includes the growth prospects of the mitotane market in the prominent LATAM countries such as Brazil, Mexico, and the Rest of Latin America.
Chapter 12 – Europe Mitotane Market Analysis 2014 - 2028 & Forecast 2019 - 2029
Important growth prospects of the mitotane market based on its end users in several countries such as Germany, the UK, France, Spain, Italy, Russia, and the Rest of Europe, are included in this chapter.
Chapter 13 – South Asia Mitotane Market Analysis 2014 - 2028 & Forecast 2019 - 2029
India, Indonesia, Thailand, and Malaysia are prominent countries in the South Asia region, which are the prime subjects of assessment to obtain growth prospects of the South Asia mitotane market in this chapter. Readers can find detailed information about the growth parameters of the South Asia mitotane market during the period of 2019-2029.
Chapter 14 –East Asia Mitotane Market Analysis 2014 - 2028 & Forecast 2019 - 2029
This chapter highlights the growth of the mitotane market in the East Asia region by focusing on China, Japan, and South Korea. This section also help readers understand the key factors that are responsible for the growth of the mitotane market in East Asia.
Chapter 15 – Oceania Mitotane Market Analysis 2014 - 2028 & Forecast 2019 - 2029
In this chapter, Australia and New Zealand are among the prominent countries in the Oceania region, which are the prime subjects of assessment to obtain the growth prospects of the Oceania mitotane market.
Chapter 16 – MEA Mitotane Market Analysis 2014 - 2028 & Forecast 2019 - 2029
This chapter provides information about how the mitotane market will grow in major countries in the MEA region, such as GCC Countries, South Africa, and the rest of MEA during the period of 2019 - 2029.
Chapter 17 – Emerging Countries Mitotane 2014-2018 and Forecast 2019-2029
The chapter provides market forecasts and analysis for key emerging countries such as China, India, and Brazil, based on key market segments considered. Besides, readers will also find a comprehensive overview of the PEST analysis and competition landscape, by country.
Chapter 18 – Market Structure Analysis
In this chapter, readers can find detailed information about the tier analysis and market concentration of the key players in the mitotane market, along with their market presence analysis by region and product portfolio.
Chapter 19 – Competition Analysis
In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the mitotane market, along with a detailed information about each company, which includes the company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are HRA Pharma Corp and Bristol-Myers Squibb Company.
Chapter 20 – Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the mitotane market report.
Chapter 21 – Research Methodology
This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about the mitotane market.
Companies covered in Mitotane Market Report
Company Profiles:
- HRA Pharma
- Bristol-Myers Squibb Company
